Atlas Trials

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Clinical trial NCT06374459 · RECRUITING

Trial details

NCT number
NCT06374459
Sponsor
Washington University School of Medicine
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Start date
2025-01-30
Primary completion
2032-05-31
Enrollment
152

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.